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Objective: To examine the effectiveness of smoking
cessation interventions in improving cessation rates
and smoking related behaviour in patients with head
and neck cancer (HNC).
Design: A systematic review of randomised and non-
randomised controlled trials.
Methods: We searched the following data sources:
CENTRAL in the Cochrane Library, MEDLINE, EMBASE,
PsycINFO and CINAHL up to February 2016. A search
of reference lists of included studies and Google
Scholar (first 200 citations published online between
2000 and February 2016) was also undertaken. The
methodological quality of included studies was
assessed using the Effective Public Health Practice
Project Quality Assessment Tool (EPHPP). 2 study
authors independently screened and extracted data with
disagreements resolved via consensus.
Results: Of the 5167 studies identified, 3 were eligible
and included in the review. Trial designs of included
studies were 2 randomised controlled trials and 1
non-randomised controlled trial. 2 studies received a
weak methodological rating and 1 received a
moderate methodological rating. The trials examine the
impact of the following interventions: (1) nurse
delivered cognitive–behaviour therapy (CBT) via
telephone and accompanied by a workbook, combined
with pharmacotherapy; (2) nurse and physician brief
advice to quit and information booklets combined
with pharmacotherapy; and (3) surgeon delivered
enhanced advice to quit smoking augmented by
booster sessions. Only the trial of the nurse delivered
CBT and pharmacotherapy reported significant
increases in smoking cessation rates. 1 study
measured quit attempts and the other assessed
consumption of cigarettes per day and readiness to
change. There was no significant improvement in quit
attempts or cigarettes smoked per day among patients
in the intervention groups, relative to control.
Conclusions: There are very few studies evaluating
the effectiveness of smoking cessation interventions
that report results specific to the HNC population. The
3 trials identified reported equivocal findings. Extended
CBT counselling coupled with pharmacotherapy may
be effective.
Trial registration number: CRD42016016421.
INTRODUCTION
Tobacco use is a key risk factor for head and
neck cancer (HNC)1 with more than 75% of
these cancers attributable to the combination
of tobacco and alcohol use.2 Human papil-
loma virus is another common cause of HNC
and smoking in this group while not causative,
has been shown to influence prognosis signifi-
cantly.3 At least one-third of patients with HNC
continue to smoke after diagnosis.4–6
Continued smoking increases risk for other
smoking-related diseases, second primary
tumours,7 disease recurrence8 and reduced
treatment efficacy, increases toxicity and side
effects from radiotherapy5 9 and negatively
affects overall survival.5 Approximately 10–12%
of patients with HNC develop a new cancer in
the head and neck region within 2–3 years
after the first cancer diagnosis.10
In addition to the diverse health benefits
of permanent smoking cessation, quitting
can have more specific benefits for patients
with a cancer diagnosis. A number of studies
have reported improvements in the progno-
sis of patients with a cancer diagnosis follow-
ing smoking cessation.5 8 11 12 For example,
quitting smoking among patients with locally
Strengths and limitations of this study
▪ To the best of our knowledge, this is the first
systematic review examining the effectiveness of
smoking cessation interventions in improving
cessation rates and smoking-related behaviour in
patients with head and neck cancer.
▪ The quality of the studies included in this review
were compromised by small sample sizes and
reliance on self-reported outcomes of smoking
cessation that were not biochemically verified in
two of the three included studies.
▪ Varying interventions, outcomes and end points,
and the limited number of studies precluded
quantitative synthesis of the trial findings.
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advanced HNC has been associated with a twofold increase
in complete response to radiation therapy.5 Abstinence
from smoking in patients with cancer has also been asso-
ciated with less pain, higher quality of life scores and better
performance status.13 Furthermore, smoking abstinence
following diagnosis reduces morbidity and mortality,5 14
particularly among those with smoking-related cancers such
as HNC and those diagnosed with a curable disease.15
Systematic reviews of smoking cessation interventions in
the general oncology population have found that high-
intensity, multicomponent interventions that include a
combination of pharmacological and behavioural
approaches are effective in improving cessation rates.16 17
However, no reviews of the effectiveness of smoking cessa-
tion interventions for patients with HNC exist. Patients
with varying types of cancer have been found to respond
differently to cessation treatment depending on the per-
ceived relevance of patient tobacco use to the onset or
recovery from cancer.18 Further, among patients with
HNC, the location of the malignancy and treatment can
cause difficulty in eating, fatigue, mucositis, dry mouth
and taste changes19 that may uniquely influence patient
receptivity to some pharmacotherapy interventions such as
nicotine gum and require a tailored approach to cessation
treatment. In addition to smoking, alcohol use is a key risk
factor for HNC and a substantial proportion continue to
drink alcohol, with ∼16% continuing to drink at hazard-
ous levels after diagnosis.4 20 Such comorbidities present
further obstacles to smoking cessation in this population21
and therefore may warrant tailored treatment.
Furthermore, research in this particular cancer population
has characterised patients with HNC as a particularly vul-
nerable group, with many living alone and having a
limited social network.22 These factors may also necessitate
extra support for patients with HNC to quit smoking.
Given the importance of ceasing tobacco use among
patients with HNC and the lack of guidance from previous
systematic reviews regarding effective cessation treatment
among this group, the primary aim of this review is to
examine the effectiveness of smoking cessation interven-
tions on smoking cessation rates in adult patients with HNC.
METHODS
This systematic review was performed in accordance with
a predetermined protocol and is reported to be consis-
tent with the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis (PRISMA) statement.23 The





Studies with the following study designs were considered
for inclusion:
▸ Randomised controlled trials, including cluster ran-
domised controlled trials;
▸ Staggered enrolment trials or stepped-wedged trials;
▸ Quasi-randomised trials;
▸ Quasi-experimental trials with comparison/control
groups, including non-randomised pre–post (before–
after) trials with one or more intervention and
control groups, time-series/interrupted time-series
trials (including multiple baseline trials) with inde-
pendent control groups, preference trials and regres-
sion discontinuity trials;
▸ Natural experiment studies that have a comparison
group.
Trials without parallel comparison or control groups
were excluded. There was no restriction based on length
of follow-up or the year of publication. Studies were
limited to those published in English in peer-reviewed
scientific journals. Comparison groups for included
trials could include no intervention controls, ‘usual’
practice or alternative interventions.
Participants
Participants of included studies were adults diagnosed
with HNC (including cancers of the nasopharynx, oro-
pharynx, oral cavity, larynx and hypopharynx) and
current smokers or those who had recently quit, due to
the potential for relapse. There were no restrictions on
type (eg, radiotherapy, surgery, chemotherapy) or stage
(eg, pre, during, post) of treatment. Studies that exami-
ned a heterogeneous group of patients with cancer but
did not report results specific to an HNC subgroup were
excluded. Studies that examined smoking cessation for
carers of patients with HNC were also excluded.
Types of interventions
Interventions that aimed to improve the smoking cessa-
tion outcomes of patients with HNC in whom part of
the intervention was conducted in a healthcare setting
(eg, clinics and hospitals) were included. Interventions
could include psychosocial and behavioural (such as
counselling, brief advice, referral, web-based information
and behavioural support) and/or pharmacological com-
ponents (medication, nicotine replacement therapy
(NRT)). Interventions targeting improvement of delivery
of smoking cessation services were included only when
data for changes in smoking outcomes of patients with
HNC were also reported. Studies that reported on
population-level public health interventions (such as
mass media campaigns, taxation and restrictions on
tobacco advertising) were excluded.
Outcomes
Primary outcome:
▸ To be included, trials needed to report a measure of
smoking cessation. This could include point preva-
lence or continuous abstinence, or current smoking
status. Smoking cessation could be assessed via self-
report (eg, interviews, questionnaires and surveys) or
biochemical measures (eg, carbon monoxide or coti-
nine assessment).
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Secondary outcomes:
▸ While not an inclusion criterion, we extracted any
additional measures of smoking behaviour reported
in trials as a study outcome including consumption of
cigarettes per day, level of nicotine dependence, quit
attempts and stage of change. Such data may be
obtained via self-report (eg, interviews, questionnaires
and surveys) or other methods.
Information sources
Electronic databases
The following electronic databases were searched for
potentially eligible studies published up to February
2016: the Cochrane Central Register of Controlled trials
(CENTRAL) in the Cochrane Library, MEDLINE (from
1946), EMBASE (from 1947), PsycINFO (from 1806)
and CINAHL (from 1937). The MEDLINE search
strategy (see online supplementary appendix A) was
adapted for other databases and included filters used in
other systematic reviews for population (patients with
HNC) and was based on the Cochrane Tobacco
Addiction Group standard review terms for health behav-
iour (smoking cessation).
Other sources
Studies were also obtained from the following sources:
▸ Reference lists of included studies;
▸ A search of Google Scholar (published online
between 2000 and February 2016—the first 200 cita-
tions were examined).
Study selection
The titles and abstracts retrieved by electronic searches
were exported to reference management software
(Endnote V.X6) to remove duplicates. References were
exported to the online software tool Covidence for
screening. One reviewer (UM) performed title and
abstract screening. Two reviewers (KM and UM) then
independently performed full-text screening, data
extraction and quality assessment. Reasons for exclusion
of full texts were recorded and documented in
figure 1. Any discrepancies were resolved by discussion
between the reviewers.
Data extraction
Two review authors (KM and UM) independently
extracted data from the included trials using a prepi-
loted data extraction form that was developed based on
recommendations from the Cochrane Handbook for
Systematic Reviews of Interventions.24 Discrepancies between
reviewers regarding data extraction were resolved by dis-
cussion and consensus. The characteristics of each study
were extracted, including study design, setting, country,
participants, gender, age, intervention characteristics
and outcomes.
Assessment of methodological quality
Studies included in the review were assessed for metho-
dological quality using the Effective Public Health
Practice Project Quality Assessment Tool (EPHPP) for
quantitative studies.25 This tool covers any quantitative
study design, includes components of intervention integ-
rity and was judged suitable for use in systematic reviews
of effectiveness.24 26 Two review authors (KM and UM)
independently assessed study quality and discrepancies
were resolved through discussion. The EPHPP assesses
six methodological dimensions: selection bias, study
design, confounders, blinding, data collection methods,
and withdrawals and dropouts. These domains are rated
on a three-point scale (strong, moderate, weak) accord-
ing to predefined criteria and procedures recom-
mended for tool use, and then given an overall global
rating. Those with no weak ratings were given an overall
rating of strong, whereas those with one weak rating
were given an overall rating of moderate and those with
two or more weak ratings across the six domains were
given an overall weak rating. Two additional methodo-
logical dimensions provided by the tool are intervention




We reported all statistically significant and non-significant
outcomes. Owing to the clinical and methodological het-
erogeneity and the small number of studies included in
the review, meta-analysis was not performed and the study
findings were synthesised narratively.
RESULTS
Search results
Abstracts of 5167 citations were screened and the full
text of 29 manuscripts was sought for further assessment
against the review inclusion criteria (figure 1). Of these,
four publications describing three trials were included
in the review.4 15 27 28
Study characteristics
A description of the trial characteristics of included
studies is provided in table 1. Included studies were pub-
lished between 1991 and 2006. Two randomised con-
trolled trials (RCTs)4 15 28 and one non-RCT27 were
identified. All trials compared interventions with a usual
care no intervention control. All three studies were con-
ducted in the USA. The interventions employed in
Gosselin et al27 and Gritz et al15 28 targeted smoking ces-
sation alone, whereas the study by Duffy et al4 targeted
multiple risk behaviours of smoking, alcohol use and
depression.
The follow-up periods varied from 1 to 12 months
postintervention. All studies were multicentre and parti-
cipants were recruited from clinics that provided care to
patients with HNC. Interventions were delivered at the
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diagnosis/treatment stage of the cancer care continuum,
including pretreatment to post-treatment. Two of the
three studies reported the location of the HNC in parti-
cipants.4 15 Only one study15 reported the type of cancer
treatment patients received (radiation or surgery).
Smoking cessation interventions were delivered by
healthcare providers and were either non-
pharmacological alone (cognitive–behaviour therapy
(CBT), self-help material, telephone counselling) or
combined with a pharmacological component (NRT,
varenicline or bupropion; table 2). In all studies, the
control group received usual care, ranging from infor-
mation on the risks of continued smoking and the bene-
fits of cessation, to handouts for resources, to referral
for smoking cessation treatment.
Methodological quality assessment
Individual ratings for each study against the six meth-
odological criteria and the assigned global rating are
reported in table 3. Overall, two studies received a
methodological quality rating of weak4 27 and one study
received a rating of moderate.15 28 Unrepresentative
samples and non-reporting of blinding of participants
and outcome assessors were key issues. Two studies
relied solely on self-reported smoking status4 27 and one
used urinary cotinine to confirm smoking status.15 28
The two additional methodological dimensions pro-
vided by the EPHPP tool, intervention integrity and ana-
lyses, were also completed. All three studies measured
the percentage of participants who received the inter-
vention as intended and were scored in the 80–100%
category on this dimension. With regard to consistency
of the interventions, Duffy et al4 did not describe
whether the intervention was provided to all participants
in the same way. Gosselin et al27 reported that a propor-
tion of the participants in the intervention condition
had multiple clinic visits compared with the other inter-
vention participants who had one visit. Gritz et al15 28
used exit checklists to ensure that their intervention was
delivered consistently, with each component delivered to
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Table 1 Trial characteristics
Author
year
(Ref) Study type Study dates
Single-centre
or
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CA, California; CBT, cognitive–behaviour therapy; EC, enhanced cessation; ENT, ear, nose and throat; FL, Florida; HNC, head and neck cancer; I, intervention; MI, Michigan; NR, not reported; NY, New York; RCT,


































Duffy et al4 Nurse administered. CBT workbook, CBT telephone
counselling (9–11 sessions)
Those who smoked were offered nicotine
replacement therapy and/or bupropion, and
those with depression were offered
antidepressants.
Enhanced usual care; referred as needed for
smoking cessation, and/or alcohol treatment,
and/or psychiatric evaluation. Handout for local,
state and national resources tailored to each
study site
Gosselin et al27 Nurse and physician administered. Inquired about
tobacco use, advised patients to quit, and offered
assistance to tobacco users interested in quitting.
Information packets were made available for staff to
give to patients who reported current tobacco use.
Attempts to contact all patients by phone within
10 days of visiting the clinic were assigned to a
designated researcher who was trained in the delivery
of support and cessation counselling components at
the New York State Smokers Quitline. They were also
contacted 1 month after clinic visit.
Prescription of stop smoking medication for
eligible patients; varenicline and bupropion
Usual care; standard tobacco cessation
practices administered by health providers with
regard to asking patients about their tobacco
use status or providing assistance to quit
smoking at Roswell Park Cancer Institute
Gritz et al15 28 Delivered by head and neck surgeons or maxillofacial
prosthodontists. Enhanced initial advice
(supplemented the usual care advice with a discussion
of the participant’s receptivity to quitting; a statement
of confidence in the participant’s ability to stop;
presentation of 3 self-help booklets; a discussion of
tobacco withdrawal; a discussion to determine a target
quit date, including joint signature of the quit-smoking
contract; and an affirmation of continuing provider
support during follow-up care) session augmented by
6 booster sessions.
Usual care; standardised advice consisting of
information on the risks of continued smoking
and the benefits of cessation for patients with
head and neck cancer. No guidelines regarding
additional advice sessions; providers were free
to follow their usual practice regarding































almost all participants in the intervention condition.
However, since the health providers in this study gave
advice in the control and intervention conditions, there
was evidence that some contamination may have
occurred. Both Duffy et al4 and Gosselin et al27 used
intent-to-treat analyses as appropriate.
Effects of intervention
Tables 3 and 4 describe the intervention characteristics
and results of the included studies, respectively. All three
included studies reported smoking cessation outcomes.
Duffy et al4 conducted an RCT to test a tailored
smoking, alcohol and depression intervention in 184
patients with HNC recruited from four hospitals in the
USA and conducted in ear, nose and throat clinics. The
CBT intervention addressed smoking, alcohol and
depression and used a workbook for patients and tele-
phone counselling delivered by nurses in combination
with NRT and/or bupropion (and antidepressants for
depression) to target comorbid conditions (smoking,
alcohol use and depression). The control group received
enhanced usual care. The primary smoking cessation
outcome in this study was self-reported smoking status
(patients asked if they were currently smoking) mea-
sured at 6 months postintervention. The authors found
that (for the 136 patients with HNC who smoked in the
past 6 months at baseline) at 6-month follow-up, the
intervention group reported significantly higher quit
rates than those in the usual care group (47% vs 31%,
p<0.05). The authors did not measure any additional
outcomes of smoking-related behaviour.
Gosselin et al27 conducted a study with a
quasi-experimental design in 179 patients with HNC
recruited from a dental/maxillofacial clinic and a head
and neck clinic in the USA. The study compared the
smoking behaviours of those who visited the clinic
during a usual care phase (standard tobacco cessation
practices) with those who visited the clinic during the
intervention phase. The intervention phase employed
nurse and physician brief advice to quit, information
booklets and pharmacotherapy (varenicline and bupro-
pion) during the clinic visit as well as a follow-up phone
call within 10 days after the clinic visit to provide cessa-
tion counselling support. The primary smoking cessation
outcome was self-reported smoking status (patients
asked if they were currently smoking) at 1-month postin-
tervention. The intervention was not effective in signifi-
cantly increasing quit rates at 1-month follow-up with
intention-to-treat (assumption that those lost to
follow-up had all returned to smoking) quit rates 8% for
the control group compared with 9% in the intervention
group.
Gosselin et al27 also measured self-reported quit
attempts (those who reported that they were currently
smoking were subsequently asked whether or not they
had made any attempt to stop smoking during the past
month) at 1-month follow-up postintervention. No sig-
nificant difference was found between intervention and
control groups. No other smoking behaviours were
reported.
Gritz et al15 28 conducted an RCT to assess the efficacy
of a provider delivered smoking cessation intervention
compared with usual care advice in 186 patients with
HNC recruited from 10 hospital or medical centre
clinics in the USA. The intervention group received
surgeon delivered enhanced advice (see table 3) to quit
smoking augmented by six monthly booster sessions
compared with a usual care control group. The authors
reported three smoking cessation outcome measures:
(1) ever quit (abstinent for 48 consecutive hours or
longer at any time during the 12-month follow-up post-
intervention period after receiving initial smoking cessa-
tion advice); (2) point prevalence abstinence (abstinent
for 48 hours or longer at the time of the 1-month,
6-month or 12-month follow-up interviews); and (3) con-
tinuous abstinence (abstinent at the 1-month, 6-month
and 12-month interviews with no smoking at all after ces-
sation). Cotinine validation of self-reported abstinence
was also conducted at each follow-up point. No signifi-
cant differences were found for any of the smoking ces-
sation outcomes.
Gritz et al15 28 also measured change in consumption
of cigarettes per day from baseline at 12-month
follow-up. Participants who were smoking at 12-month
follow-up (n=30) had significantly reduced their con-
sumption during the study, from 25.4 cigarettes/day at
baseline to 12.5 at 12 months (p=0.0001). However, rela-
tive to the control group, such reductions were not sig-
nificant. The study also reported readiness to stop using
tobacco at baseline by questionnaire and classified
according to the stage of change theory into four stages:
precontemplator (not currently thinking about stopping
smoking), contemplator (thinking of stopping within
1 year), action (quit within the past) and maintenance
(quit for 6–12 months). The authors reported a relation-
ship between cessation behaviours (at 12-month






collection Withdrawals Global rating
1. Duffy et al4 Weak Strong Strong Moderate Weak Strong Weak
2. Gosselin et al27 Moderate Strong Weak Moderate Weak Moderate Weak
3. Gritz et al15 28 Moderate Strong Strong Weak Strong Moderate Moderate
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Table 4 Tobacco smoking cessation characteristics
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cessation rates; 6 months
postintervention
Smoking cessation rates
for only those smokers with
comorbid depression and/
or alcohol (omitting those
who smoked only; n=101);
the quit rates remained
higher in the intervention
group (48%) compared
with the usual care group
(26%; p<0.05).
All patients who smoked in
the past 6 months were
included as smokers and,
as expected, those who
smoked more recently
were significantly less likely
to quit in the enhanced
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missing at random):
EC, 14% vs UC, 13%
at 1 month (NS).
ITT quit rates
(assumption that those
lost to follow-up had all
returned to smoking):
EC, 9% vs UC, 8% at
1 month (NS)
Self-reported quit attempt
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χ2 statistic was used to
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groups on smoking
behaviour reported. Quit
attempts at 1-month: I,
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(abstinent at the interview
with no smoking at all
after cessation); 1 month,




outcomes. I, 80% vs
79.8% at 1 month
(NS). I, 84.3% vs UC,
82.6% at 6 months
(NS). I, 91.4% vs UC,
89.3% at 12 months
(NS). I, 69.4% vs UC,
76.2% at 1 month
(NS). I, 71.4% vs UC,
73.9% at 6 months
(NS). I, 69% vs UC,
78.6% at 12 months
(NS). I, 69.4% vs UC,
75% at 1 month (NS).
I, 64.3% vs UC, 71%
at 6 months (NS). I,
63.8% vs UC 76.8% at
12 months (NS). Urine
samples were
collected from 83.8%




rates were 85.6% at
1 month, 91.3% at






the 96 baseline smokers
who completed the trial)
study, from 25.4 cigarettes/
day (SD=12.8) at baseline
to 12.5 (SD=8.1) at
12 months (t=7.67;
p=0.0001). No significant
difference between I and
UC participants. χ2 of the
discrepancy between
larger number of
precontemplators in I group
and larger number of
participants in the action
stage of change in the UC
group (p=0.017) Stepwise
logistic regression; action
stage of change (p=0.0004)
entered the model as
significant.






























follow-up) and baseline readiness to change in the 96
patients who were classified as baseline smokers in their
study (p=0.002). Rates of continuous abstinence at
12-month follow-up were lowest for those in the precon-
templation stage and highest for those in the action
stage of change at baseline. No other smoking beha-
viours were reported as outcomes in the trial.
DISCUSSION
The objective of the present review was to examine the
effectiveness of smoking cessation interventions to
improve cessation rates in patients with HNC. Despite
including both randomised and non-randomised trials,
the review identified only three eligible studies. Of
these, only one reported significant improvements in
cessation rates at follow-up. These findings highlight the
lack of robust smoking cessation intervention research
conducted among patients with HNC, a group where
ceasing tobacco use is particularly important.
All three studies employed interventions delivered by
a health provider involved in the care of patients with
HNC. Health professionals in the oncology setting are
well positioned to deliver smoking cessation interventions
and indeed numerous best practice guidelines recom-
mend that those involved in the care of patients with
cancer assess smoking status and offer support to quit.29
Interestingly, however, trials testing (1) nurse and physi-
cian brief advice to quit and information booklets com-
bined with pharmacotherapy; and (2) surgeon delivered
enhanced advice to quit smoking augmented by booster
sessions were ineffective. Such findings are consistent
with previous trials and reviews of physician-administered
and nurse-administered interventions for patients with
cancer who have found that relatively brief interventions
are ineffective.29–31 Patients with smoking-related
cancers generally have high levels of nicotine depen-
dence, which affects quitting success.29 32 More intensive
smoking cessation interventions may be required to
improve quit rates in this population.
Indeed, the only study in this review to find statistically
significant differences between intervention and control
groups on the primary cessation outcome was Duffy
et al.4 The intervention used in this study was high inten-
sity and multicomponent, with up to 11 telephone coun-
selling sessions that targeted multiple risk behaviours
with CBT and pharmacotherapy. This finding suggests
that low-intensity or single intervention components that
are sufficient for other patient groups may not be
adequate to achieve cessation among patients with HNC
characterised by long histories of heavy smoking and
high nicotine dependence.33 34 Smoking cessation
research in hospitalised patients has found that intensive
smoking cessation interventions combining behavioural
interventions with cessation medication maximise the
likelihood of a positive long-term cessation outcome.35–37
Further trials of smoking cessation interventions in
patients with HNC are needed to test this hypothesis,
specifically randomised comparisons of long-term bio-
chemically verified smoking cessation outcomes between
patients receiving high-intensity, combined behavioural
intervention and pharmacotherapy with low-intensity
single component interventions.
Our finding also fits with the results of previous
research that integrated treatment is effective for coexis-
ting problems.16 38 39 The health behaviours of patients
with HNC, particularly smoking and drinking, are highly
inter-related. A large proportion of patients with HNC
who smoke also have a history of regularly consuming
alcohol.21 Difficulties with nutrition due to the malig-
nancy and treatment have been associated with smoking
and problem drinking in HNC.40 Given the
co-occurrence of these behaviours in addition to the
high rate of depression found in this group, addressing
the interaction between smoking, drinking and depres-
sion in patients with HNC may be more beneficial for
smoking cessation outcomes than targeted smoking
treatment that ignores these other factors. The authors
would cautiously suggest that multicomponent and inte-
grated treatment be clinically recommended where avail-
able, while the evidence base is improved.
An important limitation of the review was the quality
of studies included. Two studies received a methodo-
logical rating of weak and one received a rating of mod-
erate. Although two of the three studies used a RCT
design, the sample sizes were relatively small with the
number of participants below 200 for all three studies.
Only Gritz et al15 28 confirmed smoking cessation status
with biochemical verification. Biochemical verification of
smoking status is recommended in studies of smoking
cessation in medical populations with smoking related
diseases.41 Research suggests that biochemical verifica-
tion of current smoking status among patients with
cancer can be as much as 20% higher than self-
report.42 43 As such, the cessation outcomes reported in
the included trials may represent an overestimate.
Additionally, varying interventions, outcomes and end
points, as well as the limited number of studies, pre-
cluded quantitative synthesis of the trial findings. While
the review methods were based on the Cochrane hand-
book, the search was restricted to English language peer-
reviewed publications. In doing so, the review may not
have captured all relevant studies in the field.
CONCLUSIONS
There are very few studies evaluating the effectiveness of
smoking cessation interventions that report results spe-
cific to the HNC population. The results of this review
indicate that a multicomponent approach may benefit
patients with HNC who continue to smoke after diagno-
sis. However, this finding is based on one study, and
therefore the current state of evidence does not allow
for a recommendation of any specific form of smoking
cessation treatment, in particular for this cancer group.
There is much scope for developing the evidence base
10 McCarter K, et al. BMJ Open 2016;6:e012296. doi:10.1136/bmjopen-2016-012296
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in this area. Given the significance of tobacco smoking
as a key risk factor for HNC and its impact on treatment
outcomes and further disease, it is imperative that
further studies with strong methodological quality and
standardised outcome measures are conducted in this
population to guide development of smoking cessation
programmes.
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